IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by V Square Quantitative Management LLC

V Square Quantitative Management LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,872 shares of the company’s stock after buying an additional 59 shares during the period. V Square Quantitative Management LLC’s holdings in IDEXX Laboratories were worth $912,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Riverview Trust Co purchased a new position in IDEXX Laboratories in the first quarter valued at approximately $26,000. Crewe Advisors LLC acquired a new position in IDEXX Laboratories during the first quarter worth $26,000. Institutional & Family Asset Management LLC acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth $28,000. DSM Capital Partners LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth about $33,000. Finally, Private Wealth Management Group LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 2.6 %

Shares of NASDAQ IDXX traded down $12.60 during mid-day trading on Wednesday, reaching $475.22. The company had a trading volume of 286,032 shares, compared to its average volume of 489,530. The stock’s 50 day moving average is $485.53 and its 200-day moving average is $512.33. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The stock has a market capitalization of $39.25 billion, a PE ratio of 45.85, a price-to-earnings-growth ratio of 3.91 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business earned $2.67 EPS. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares of the company’s stock, valued at approximately $87,068.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.11% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on IDXX. Barclays reduced their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Piper Sandler reduced their target price on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Finally, Morgan Stanley reduced their price objective on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.